Mercer Global Advisors’s BridgeBio Pharma BBIO Stock Holding History

Mercer Global Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$251K	Buy	+3,375	New	+$236K	﹤0.01%	3012
2024 Q3	–	Sell	-14,198	Closed	-$360K	–	1961
2024 Q2	$360K	Sell	14,198 -73	-0.5%	-$2K	﹤0.01%	1488
2024 Q1	$441K	Buy	14,271 +99	+0.7%	+$3.37K	﹤0.01%	1346
2023 Q4	$572K	Buy	14,172 +59	+0.4%	+$1.77K	﹤0.01%	1238
2023 Q3	$372K	Hold	14,113	–	–	﹤0.01%	1404
2023 Q2	$243K	Buy	14,113 +3,613	+34%	+$54.4K	﹤0.01%	1633
2023 Q1	$174K	Sell	10,500 -39	-0.4%	-$455	﹤0.01%	1757
2022 Q4	$80K	Hold	10,539	–	–	﹤0.01%	1838
2022 Q3	$105K	Buy	+10,539	New	+$109K	﹤0.01%	1713

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Mercer Global Advisors's BBIO Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 3,375 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #3012 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in BBIO as recently as Q2 2024.

Mercer Global Advisors first reported a position in BBIO in Q3 2022 and has held it in 9 quarters since. The position peaked at $572K in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Mercer Global Advisors held 3,375 shares of BridgeBio Pharma worth $251K as of Q2 2026.
BridgeBio Pharma was a new Mercer Global Advisors position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3012 holding.
Mercer Global Advisors first reported a position in BridgeBio Pharma in Q3 2022 and has held it in 9 quarters since.
Mercer Global Advisors's BridgeBio Pharma position peaked at $572K in Q4 2023.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.